Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated August 31, 2018 (the "Prospectus") issued by Hua Medicine (the "Company").

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in ortŸúü²áðthe Comp

made under the United States Investment Company Act of 1940.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Potential investors of the Offer Shares should note that the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, September 14, 2018).

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilizing manager (the "Stabilizing Manager"), its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Friday, October 5, 2018 being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



HUA MEDICINE

6 ï < [1]

(Incorporated in the Cayman Islands with limited liability)

Global Offering

Number of Offer Shares under the Global Offering	:	104,756,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	5,217,500 Shares (as adjusted after reallocation)
Number of International Offer Shares	:	99,538,500 Shares (as adjusted after reallocation and subject to the Over-allotment Option)
Final Offer Price	:	HK$8.28 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	:	US$0.001 per Share
Stock code	:	2552

Joint Sponsors

SUMMARY

Applications and Indication of Interest Received

- The Offer Price has been determined at HK$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%). Based on the Offer Price of HK$8.28 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK$780.6 million (subject to rounding), assuming the Over-allotment Option and the Post-IPO Share Option are not exercised. The Company intends to apply such net proceeds for the following purposes:

  - approximately 39% of the net proceeds, or HK$304.4 million, will be used for completing the Phase III trials of Dorzagliatin, for both monotherapy and combination trials with metformin;

  - approximately 9% of the net proceeds, or HK$70.3 million, will be used for further research and development involving Dorzagliatin, which will include combination trials;

  - approximately 27% of the net proceeds, or HK$210.8 million, will be used for the launch and commercialization of Dorzagliatin in China, including marketing, sales and manufacturing;

  - approximately 11% of the net proceeds, or HK$85.9 million, will be used for further research on mGLUR5, fixed dose combinations involving Dorzagliatin and personalized diabetes studies;

  - approximately 4% of the net proceeds, or HK$31.2 million, will be used for exploring additional licensing and partnership opportunities directly relating to diabetes or new therapeutic areas for which we believe there is a significant unmet medical need; and

  - approximately 10% of the net proceeds, or HK$78.1 million, will be used for our general corporate and working capital purposes.

  For details of the use of proceeds, see “Future Plans and Use of Proceeds” in the Prospectus.

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been undersubscribed. The final number of Offer Shares under the Hong Kong Public Offering is 5,217,500 Offer Shares, representing 4.98% of the total number of Offer Shares initially available under the Global Offering. A total of 1,922 valid applications have been received pursuant to the Hong Kong Public Offering on WHITE and YELLOW Application Forms and through giving electronic application instructions to HKSCC via CCASS and under the HK eIPO White Form service (www.hkeipo.hk) for a total of 5,217,500 Hong Kong Offer Shares, representing approximately 0.50 times of the total number of 10,476,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.

- Due to the under-subscription in the Hong Kong Public Offering, the Joint Global Coordinators have exercised their discretion to reallocate unsubscribed Offer Shares under the Hong Kong Public Offering to the International Offering as described in the sub-section headed "Structure of the Global Offering — Reallocation" in the Prospectus. A total number of 5,258,500 Offer Shares initially available for subscription under the Hong Kong Public Offering have been reallocated to the International Offering. As a result of such reallocation, the final number of Shares under the International Offering has been increased to 99,538,500 Offer Shares, representing approximately 95.02% of the total number of Offer Shares in the Global Offering (before any exercise of the Over-allotment Option and the Post-IPO Share Option).

International Offering and the Over-allotment Option

- The Offer Shares initially offered under the International Offering have been moderately over-subscribed. The final number of Offer Shares allocated to the placees under the International Offering comprises 99,538,500 Offer Shares, representing 95.02% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option and the Post-IPO Share Option). A total of 100 placees have been allotted no more than three board lots of Offer Shares, representing approximately 75.8% of the 132 placees under the International Offering, being the total number of placees under the International Offering. These placees have been allotted 0.12% and 0.10% of the Offer Shares, before over-allocation and post over-allocation respectively, under the International Offering.

- We have applied to the Stock Exchange for, and the Stock Exchange has granted us waivers from strict compliance with Rule 10.04 of the Rules governing the Listing of Securities on the Stock Exchange (the "Hong Kong Listing Rules") and consents under Paragraph 5(2) of Appendix 6 to the Hong Kong Listing Rules (the "Placing Guidelines") to permit the Company to allocate Shares to ABG II-Hua Limited ("ABG"), GIC Private Limited ("GIC

- Pursuant to the International Underwriting Agreement, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company, and be available on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk As of the date of this announcement, the Over-allotment Option has not been exercised.

- Save as disclosed above and in the Prospectus, the International Offering is in compliance with the Placing Guidelines. No Offer Shares placed by or through the Joint Global Coordinators and the Underwriters under the Global Offering have been placed with any core connected person (as such term is defined in the Hong Kong Listing Rules) of the Company or, save as disclosed in the foregoing to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees. The Directors confirm that no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering.

Results of Allocations

- The final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on or before Thursday, September 13, 2018 in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese) and on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk

- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering, including applications made under WHITE and YELLOW Application Forms and by giving electronic application instructions to HKSCC or through the designated HK eIPO White Form service, which will include the Hong Kong identity card numbers, passport numbers or Hong Kong business registration numbers of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:

  - in the announcement to be posted on the Stock Exchange's website at www.hkexnews.hk and on the Company's website at www.huamedicine.com by no later than 9:00 a.m. on Thursday, September 13, 2018;

  - from the designated results of allocation website at www.tricor.com.hk/ipo/result with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Thursday, September 13, 2018 to 12:00 midnight on Wednesday, September 19, 2018;

  - by telephone enquiry line by calling 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, September 13, 2018 to Tuesday, September 18, 2018 on a business day; and

  - in the special allocation results booklets which will be available for

- Share certificates for Hong Kong Offer Shares allotted to applicants using WHITE Application Forms or HK eIPO White Form service, which are either not available for personal collection, or which are available but are not collected in person within the time specified for collection, are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on Thursday, September 13, 2018.

- Wholly successful applicants using YELLOW Application Forms or by giving electronic application instructions to HKSCC will have their share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant as

€ Refund monies (if any) for applicants giving electronic application instructions to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker or custodian on Thursday, September 13, 2018.

Public Float

€ The Directors of the Company confirm that the market capitalization of the number of Shares to be held by the public will satisfy the minimum requirement prescribed under Rule 18A.07 of the Listing Rules that a portion of the total number of the Shares with a market capitalisation of at least HK$375 million are held by the public at the time of the Listing. The Directors of the Company confirm that the three largest public shareholders of the Company do not hold more than 50% of the Shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules. The Directors of the Company confirm that there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

Commencement of Dealings

€ Share certificates issued in respect of the Hong Kong Offer Shares will only become valid certificates of title at 8:00 a.m. on Friday, September 14, 2018 provided that the Global Offering has become unconditional in all respects and the right of termination as described in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for termination" in the Prospectus has not been exercised.

€ The Company will not issue any temporary documents of title in respect of the Hong Kong Offer Shares. No receipt will be issued for application monies received.

€ Dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Friday, September 14, 2018. The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 2552.

Investor should be aware that the concentration of the Shareholders may affect the liquidity of the Shares. Consequently, Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

APPLICATIONS AND INDICATION OF INTEREST RECEIVED

The Offer Price has been determined at HK$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%). Based on the Offer Price of HK$8.28 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and estimated

Applications not completed in accordance with the instructions set out in the Application Forms have been rejected. No multiple applications or suspected multiple applications have been identified and rejected. One application has been rejected due to bounced cheques. No application has been rejected due to invalid applications. No application for more than 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering (that is, more than 5,238,000 Hong Kong Offer Shares) has been identified.

Due to the under-subscription in the Hong Kong Public Offering, the Joint Global Coordinators have exercised their discretion to reallocate unsubscribed Offer Shares under the Hong Kong Public Offering to the International Offering as described in the sub-section headed "Structure of the Global Offering — Reallocation" in the Prospectus. A total number of 5,258,500 Offer Shares initially available for subscription under the Hong Kong Public Offering have been reallocated to the International Offering. As a result of such reallocation, the final number of Shares under the International Offering has been increased to 99,538,500 Offer Shares, representing approximately 95.02% of the total number of Offer Shares in the Global

Placees with Waivers under Rule 10.04 of the Hong Kong Listing Rules and Consents under Paragraph 5(2) of the Placing Guidelines

Certain Offer Shares were placed to close associates or affiliate of certain existing indirect or direct shareholders of the Company, details of which are set out below:

Placee	Number of Offer Shares placed	Approximate % of the Offer Shares*	Approximate % of the total issued share capital following the completion of the Global Offering*	Relationship with the existing shareholder of the Company
ABG II-Hua Limited ("ABG")	2,350,000 ("ABG Placement")	2.24	3.66	ABG is an existing shareholder
GIC Private Limited ("GIC")	2,350,000 ("GIC Placement")	2.24	3.07	The existing shareholder, Tetrad Ventures Pte. Ltd. is a limited company established and managed by GIC Special Investments Pte. Ltd., which is wholly-owned by GIC
BlackRock Asset Management North Asia Limited ("BAMNA")[(2)]	10,852,500 (" Placement")	10.36	1.77	BlackRock Funds are existing shareholders and BAMNA is an affiliate of the BlackRock Funds
Raymond James & Associate ("Raymond")	45,000 ("Raymond Placement")	0.04	2.59	John J. Baldwin is a client of Raymond James & Associates Inc, which is a non-discretionary fund holding investment on behalf of John J. Baldwin and John J. Baldwin makes the ultimate investment decisions. John J. Baldwin, Ann M. Baldwin, Alysia Baldwin Ferro, Tracy Baldwin and John K. Baldwin are within the same family ("Baldwin Family") and are existing shareholders

rights with regard to the Company surviving the Listing, we have applied to the Stock Exchange for, and the Stock Exchange has granted us a waiver from Rule 10.04 of the Hong Kong Listing Rules and a consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate Shares to each of ABG, GIC, BAMNA (for and on behalf of the BlackRock Funds and other funds and accounts managed by the investment manager of the BlackRock Funds and Raymond, and the relevant allocations of Shares are in compliance with all the conditions under the consent granted by the Stock Exchange.

In respect of the ABG Placement, GIC Placement, BAMNA Placement and Raymond Placement, (A) each of ABG, GIC, BAMNA and Raymond has confirmed to the Company, the Joint Sponsors and the Joint Bookrunners that (i) they are not connected persons of the Company (as defined in the Listing Rules) and are not accustomed to take instructions from a connected person in relation to the acquisition, disposal, voting or other disposition of Shares held or to be allotted to them; (ii) they are not persons who will become connected persons of the Company immediately upon completion of the Global Offering; and (iii) their subscription for Shares is not being financed by or being made on instruction of any of the connected persons of the Company; (B) Company has confirmed that no preferential treatment has been, nor will be, given to each of ABG, GIC, BAMNA and Raymond or their close associates by virtue of their relationship with the Company in the allocation process under the placing tranche, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement; and (C) the Joint Bookrunners has confirmed, to the best of their knowledge and belief, that no preferential treatment has been, nor will be, given to each of ABG, GIC, BAMNA and Raymond or their close associates by virtue of their relationship with the Company in any allocation in the allocation process under the placing tranche, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement. Based on (a) the foregoing Company's and Joint Bookrunners' confirmations and (b) the Joint Sponsors discussion with the Company and the Joint Bookrunners, and to the best of our knowledge and belief, the Joint Sponsors have no reasons to believe that ABG, GIC, BAMNA and Raymond or any of their close associates received or will receive any preferential treatment in the IPO allocation as a placee by virtue of its relationship with the Company, and details of the allocation to each of ABG, GIC, BAMNA and Raymond will be disclosed in this announcement.

Pursuant to the International Underwriting Agreement, the Company has granted the Over- allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the paragraph headed "Structure of the Global Offering — Conditions of the Global Offering" in the Prospectus, valid applications made by the public on WHITE and YELLOW Application Forms and through giving electronic application instructions to HKSCC via CCASS and to the HK eIPO White Form Service Provider under the HK eIPO White Form service will be conditionally allocated on the basis set out below:

The final number of Offer Shares comprised in the Hong Kong Public Offering is 5,217,500 Offer Shares, representing 4.98% of the total number of the Offer Shares initially available under the Global Offering.

RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering, including applications made under FormsSandbygiviongelectrfaapplicatioSinstrucations

the

Wing Lung Bank Limited

	Branch Name	Address
Hong Kong Island	Head Office	45 Des Voeux Road Central
	Johnston Road Branch	118 Johnston Road
	Kennedy Town Branch	28 Catchick Street
Kowloon	Mong Kok Branch	Basement, Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
New Territories	Tsuen Wan Branch	251 Sha Tsui Road


The final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on or before Thursday, September 13, 2018 in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese) and on the Company's website at www.huamedicine.com and the website of the Stock Exchange at www.hkexnews.hk.

SHAREHOLDING CONCENTRATION ANALYSIS

5HVXOWV RI $SSOLFDWLRQV 0DGH E\ :+,7($SSOLFDWLRQ)RUPV RU +. H,32 :KLWH)R
7KH IROORZLQJV DUH WKH LGHQWLILFDWLRQ GRFXPHQW QXPEHUV ZKHU+H7(XSSOLH
$SSOLFDWLRQ.)R,32V.KLWHDQGRUW WKH QXPEHU RI +RQJ .RQJ 2IIHU 6KDUHV FRQGLWLRQ
ZKR KDYH QRW SURYLGHG WKHLU LGHQWLILFDWLRQ GRFXPHQW QXPEHUV DUH QRW
以白色申

發

股份



DESPATCH/COLLECTION OF SHARE CERTIFICATES AND REFUND CHEQUES

Applicants who have applied for 1,000,000 Hong Kong Offer Shares or more and are successfully allocated Hong Kong Offer Shares and have provided all information required by their WHITE Application Forms, and applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the HK eIPO White Form service by submitting electronic applications through the designated website www.hkeipo.hk and whose applications are wholly successful, may collect their share certificate(s) (where applicable) in person from Tricor Investor Services Limited at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, September 13, 2018 or such other date as notified by the Company in the newspapers.

Applicants being individuals who are eligible for personal collection cannot authorize any other person to make the collection on their behalf. Corporate applicants which opt for personal collection must attend by their authorized representatives bearing letters of authorization from their corporations stamped with the corporations' chops. Both individuals and authorized representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Tricor Investor Services Limited.

Share certificates for Hong Kong Offer Shares allotted to applicants using WHITE Application Forms or HK eIPO White Form service, which are either not available for personal collection, or which are available but are not collected in person within the time specified for collection, are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on Thursday, September 13, 2018.

Wholly successful applicants using YELLOW Application Forms or by giving electronic application instructions to HKSCC will have their share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant as instructed by the applicants in the YELLOW Application Forms or any designated CCASS Participants giving electronic application instructions on their behalf on Thursday, September 13, 2018.

Applicants applying through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.

Applicants applying as a CCASS Investor Participant YELLOW Application Forms or by giving electronic application instructions to HKSCC via CCASS should check the announcement made by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Thursday, September 13, 2018 or such other date as shall be determined by HKSCC or HKSCC N(minedes)-34735(Hpplicants)-538.5(Hpplyi

Refund monies (if any) for applicants giving electronic application instructions to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker or custodian on Thursday, September 13, 2018.

OVER-ALLOTMENT OPTION

Pursuant to the International Underwriting Agreement, the Company has granted the Over- allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) from the Listing Date up to and including Friday, October 5, 2018, being the 30th day from the last day for the lodging of applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000 additional Offer Shares at the Offer Price under the International Offering, representing approximately 15% of the Offer Shares initially available under the Global Offering. There has been an over-allocation of 15,713,000 Shares in the International Offering. Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company. As of the date of this announcement, the Over-allotment Option has not been exercised.

NET PROCEEDS OF THE GLOBAL OFFERING

Based on the Offer Price of HK$8.28 per Offer Share (exclusive of brokerage fee of

€

Global Offering has become unconditional in all respects and the right of termination as described in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — The Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination" in the Prospectus has not been exercised.

Assuming that the Global Offering becomes unconditional in all aspects at 8:00 a.m. on Friday, September 14, 2018, dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, September 14, 2018. Shares will be traded in board lots of 500 Shares. The stock code of the Shares is 2552.

By order of the Board of Directors
HUA MEDICINE
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, September 13, 2018

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.*

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Journal (in Chinese).

* The appointment of Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors will take effect on the Listing Date.